Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study.

J Headache Pain · 2021 · PMC8903705 · PMID 34922444

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

nearly significantp = .054so close (0.05 < p ≤ 0.1)

No significant difference was observed between CM and HFEM patients, although the comparison for the first month of follow-up was nearly significant (Mann-Whitney U test; F-UP1: p = .054; F-UP2: p = .692; F-UP3: p = .144).

also in 3,287 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.